Symberix Overview

  • Founded
  • 2012
  • Status
  • Private
  • Latest Deal Type
  • Debt
  • Latest Deal Amount
  • $250K
Latest Deal Amount

Symberix General Information


Provider of biological research services. The company's research discovers a way to target enzymes produced by the gut microbiome, which causes chemotherapeutic side effects. It identifies a link between microbial changes in the gut and the dose-limiting gastrointestinal side effects of certain drugs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Drug Discovery
Primary Office
  • 4819 Emperor Boulevard
  • Suite 400
  • Durham, NC 27703
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Symberix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Debt - General 09-Feb-2018 $250K 00.000 Completed Startup
2. Grant 06-Aug-2014 00000 00.00 Completed Startup
1. Angel (individual) $3.5M $3.5M Completed Startup
To view Symberix’s complete valuation and funding history, request access »

Symberix Executive Team (3)

Name Title Board Seat Contact Info
Ward Peterson Ph.D Co-Founder, Chief Executive Officer & President
Matthew Redinbo Ph.D Co-Founder, Board of Director & Chief Scientific Officer
Greg Mossinghoff Chief Business Officer
To view Symberix’s complete executive team members history, request access »